NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) - Dilution Analysis

10-Q filing | 26.0M shares outstanding

8-K filing: NeOnc Technologies Holdings, Inc. issued shares and warrants through multiple closings under four Securities Purchase Agreements, with the proceeds intended to fund preclinical trials. ($15.07M proceeds)

S-3 filing: The company is filing an S-3 to register an indeterminate number of shares of common stock and preferred stock, an indeterminate principal amount of debt securities, an indeterminate number of warrants and rights to purchase common stock, preferred stock, or debt securities, and an indeterminate number of units, with an aggregate initial offering price not to exceed $300,000,000.

10-K filing | 23.8M shares outstanding

10-Q filing | 19.2M shares outstanding

S-1 filing: The company entered into agreements to sell 624,999 shares of common stock at $16.00 per share for gross proceeds of approximately $10,000,000 in a private placement.

8-K filing: NeOnc Technologies Holdings, Inc. entered into an employment agreement with Josh Neman for his service as Chief Clinical Officer, including a grant of 200,000 restricted stock units under the 2023 Equity Incentive Plan.

10-Q filing | 18.1M shares outstanding

S-1 filing: S-1 filing for registration of common stock.

8-K filing: NeOnc Technologies Holdings, Inc. entered into an Office Lease with RREF II Calabasas Park Center LLC for its new principal executive offices.

8-K filing: NeOnc Technologies Holdings, Inc. entered into securities purchase agreements to issue and sell shares of common stock at $16.00 per share, for gross proceeds of approximately $1.6 million. ($1.6M proceeds)

S-1/A filing: This S-1/A filing registers shares of common stock to be sold pursuant to a private placement at a price of $16.00 per share.

S-1/A filing: Registration of 624,999 shares of common stock to be sold at a private placement price of $16.00 per share for gross proceeds of approximately $10,000,000.

S-1 filing: This is an S-1 filing for NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, for an offering of common stock and to convert previous debt, and to engage a placement agent for the sale of shares of common stock in a private placement.

S-1/A filing: This is the initial public offering of 6,000,000 shares of common stock of NeOnc Technologies Holdings, Inc.

S-1/A filing: This is an S-1/A filing for the initial public offering of NeOnc Technologies Holdings, Inc., offering 3,797,470 shares of common stock at an expected price range of $18.75 to $20.75 per share.

S-1/A filing: This is an S-1/A filing for the initial public offering of NeOnc Technologies Holdings, Inc., involving 3,797,470 shares of common stock with an anticipated price range of $18.75 to $20.75 per share.

S-1/A filing: This S-1/A filing relates to a proposed offering of common stock, with Maxim acting as underwriter and financial advisor. The company intends to list its common stock on the Nasdaq Capital Market under the symbol 'NTHI.' The principal purposes of this offering are to increase our capitalization and financial flexibility and create a public market for our common stock.

S-1 filing: S-1 filing for an IPO of common stock, with an over-allotment option for underwriters. The company intends to list its common stock on the Nasdaq Capital Market under the symbol "NTHI."